AmCad BioMed Corporation (TPEX:4188)
Taiwan
· Delayed Price · Currency is TWD 13.50
+0.10 (0.75%)
Apr 28, 2025, 1:30 PM CST
AmCad BioMed Revenue
In the year 2024, AmCad BioMed had annual revenue of 53.11M TWD, down -18.62%. AmCad BioMed had revenue of 18.14M in the quarter ending December 31, 2024, a decrease of -22.52%.
Revenue
53.11M
Revenue Growth
-18.62%
P/S Ratio
15.98
Revenue / Employee
1.56M
Employees
34
Market Cap
848.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 53.11M | -12.15M | -18.62% |
| Dec 31, 2023 | 65.26M | 3.63M | 5.88% |
| Dec 31, 2022 | 61.63M | -24.16M | -28.16% |
| Dec 31, 2021 | 85.79M | 21.85M | 34.17% |
| Dec 31, 2020 | 63.94M | -20.15M | -23.96% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 9.73B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Polaris Group | 107.00M |
| Oneness Biotech | 117.93M |
| Lumosa Therapeutics | 39.15M |
| Pegavision | 6.82B |